Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Jason Matuszewski is Chief Executive Officer at Biostem Technologies. OQRO lists 3 transactions filed with the SEC under this name, the latest on Nov 19, 2026, each linked to the official Form 4.
Chief Executive Officer
Disclosures on record
3
Companies involved
1
Biostem TechnologiesBSEM
3 disclosures · Oct 2026 – Nov 2026 · 1 sold
Nov 17, 2026Sold~$14Kdisclosed Nov 19
DetailsOfficial recordOct 7, 2026250Kdisclosed Oct 9
DetailsOfficial recordOct 7, 2026250Kdisclosed Oct 9
DetailsOfficial recordAs of the latest filing on , Jason Matuszewski reported holding 1,539,251 shares of Biostem Technologies (BSEM), worth about $978K at the last close of $1 (Nov 20, 2026). In the last 12 months, Jason Matuszewski sold $14K in 1 sale.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Biostem Technologies BSEM | 1,539,251 | 1.54M direct | $1 | $978K | Nov 17, 2026 |
Is this Jason Matuszewski’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Jason Matuszewski has no open-market purchase on record since 2026. Sales in 1 of the 1 years since 2026.
Jason Matuszewski reported 0 open-market purchases and 1 sale since 2026; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $14K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Nov 17, 2026, Jason Matuszewski reported holding 1,539,251 shares of Biostem Technologies (BSEM). At the last close of $1 on Nov 20, 2026, that is about $978K. This is the stake disclosed in filings, not a net worth.
No public filing gives Jason Matuszewski's net worth. What SEC Form 4 shows is the stock stake: 1,539,251 shares of Biostem Technologies (BSEM), about $978K at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
In SEC filings of the last 12 months, Jason Matuszewski reported 1 open-market sale worth $14K, and no open-market purchase. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Jason Matuszewski has no open-market purchase on record since 2026. Sales in 1 of the 1 years since 2026.
In SEC filings since 2026: no open-market purchase is on record; the latest open-market sale is from 2026.
Biostem Technologies (BSEM), from 2026 to 2026: 0 purchases and 1 sale.
Jason Matuszewski reported 0 open-market purchases and 1 sale here, 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.